Antoine Papiernik - Mar 10, 2022 Form 4 Insider Report for Shockwave Medical, Inc. (SWAV)

Role
Director
Signature
/s/ Wade Estey, as attorney-in-fact for Antoine Papiernik
Stock symbol
SWAV
Transactions as of
Mar 10, 2022
Transactions value $
-$9,802,757
Form type
4
Date filed
3/11/2022, 05:44 PM
Previous filing
Jul 9, 2021
Next filing
Jun 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWAV Common Stock Sale -$888K -5.49K -4.49% $161.61 117K Mar 10, 2022 By Sofinnova Capital VII FCPR F1, F2
transaction SWAV Common Stock Sale -$2.91M -17.9K -15.34% $162.51 98.9K Mar 10, 2022 By Sofinnova Capital VII FCPR F2, F3
transaction SWAV Common Stock Sale -$3.18M -19.4K -19.65% $163.53 79.4K Mar 10, 2022 By Sofinnova Capital VII FCPR F2, F4
transaction SWAV Common Stock Sale -$2.09M -12.7K -16.03% $164.43 66.7K Mar 10, 2022 By Sofinnova Capital VII FCPR F2, F5
transaction SWAV Common Stock Sale -$735K -4.45K -6.67% $165.40 62.3K Mar 10, 2022 By Sofinnova Capital VII FCPR F2, F6
holding SWAV Common Stock 3.55K Mar 10, 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $161.00 to $161.96. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F2 Represents shares directly held by Sofinnova Capital VII FCPR. The reporting person is one of the managing partners of Sofinnova Partners SAS, a French corporation and the management company of Sofinnova Capital VII FCPR. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
F3 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $162.00 to $162.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F4 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $163.00 to $163.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F5 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $164.03 to $164.94. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F6 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $165.25 to $165.40. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.